SCHEMBL23213588

SCHEMBL23213588

Cc1c(Cl)cc(NC(=O)O)cc1CN1CCN(C)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.49
GSPT1 P15170 1/20 0.47
CRBN Q96SW2 1/20 0.47
KIT P10721 2/20 0.42
POLB P06746 2/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
FAAH O00519 1/20 0.41
TP53 P04637 1/20 0.41
ADORA1 P30542 1/20 0.41
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
PKM P14618 1/20 0.40
BTK Q06187 1/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
HIF1A Q16665 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26633260 0.86 CNR2 (0.56) GSPT1CRBNPOLBALDH1A1CNR1
SCHEMBL29716288 0.84 GAA (0.52) ABL1GSPT1CRBNPOLBALDH1A1
SCHEMBL23240068 0.84 GAA (0.52) ABL1GSPT1CRBNPOLBALDH1A1
SCHEMBL25292715 0.84 ABL1 (0.57) ABL1KITPOLBKDM4EALDH1A1
SCHEMBL23213615 0.82 CNR1 (0.41) GSPT1CRBNPOLBTP53CNR1
SCHEMBL23214090 0.78 GSPT1 (0.53) GSPT1CRBNKDM4EALDH1A1CNR1
SCHEMBL23213302 0.78 GSPT1 (0.49) GSPT1CRBNCNR1CNR2HRH3
SCHEMBL23214232 0.78 CNR1 (0.41) GSPT1CRBNCNR1CNR2KMT2A
SCHEMBL27290060 0.77 ALDH1A1 (0.50) POLBKDM4EALDH1A1TDP1GLA
SCHEMBL23213589 0.75 LMNA (0.50) POLBKDM4EALDH1A1TDP1ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS MONTE ROSA THERAPEUTICS AG (CH) 2024-07-04 US disclosed
EP-4313047-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS Monte Rosa Therapeutics, Inc. (US) 2024-02-07 EP disclosed
WO-2021069705-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS (CH) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS UPF1, NSUN2, RTF2 ABL1 3276/4885GSPT1 1795/4885CRBN 524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.